版本:
中国

BRIEF-FDA provides Cornerstone Pharmaceuticals approval to initiate pivotal study for CPI-613

March 23 Idt Corp

* FDA provides cornerstone pharmaceuticals approval to initiate pivotal study for CPI-613, its metabolism-directed anticancer compound Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐